New Delhi: Ha e arabela tlhahiso ea Fresenius Medical Care, Komiti ea Litsebi tse Ikhethang (SEC) ea Mokhatlo oa Central Drugs Standard Control Organisation (CDSCO) e khothalelitse k'hamphani ho fana ka mabaka a tumello hammoho le lintlha tsa teko ea kliniki ea mohato oa III oa calcium chloride dihydrate le lintlha tsa tlhokomelo ea kamora ho bapatsa tse tsoang linaheng tse amohetsoeng bakeng sa ho nahanoa ka ho eketsehileng.
Khamphani e kile ea etsa kopo ea ho hlahisa le ho rekisa tharollo ea calcium chloride dihydrate ka tekanyo ea 100 mmol/L, e sebelisoang bakeng sa "phekolo ea calcium e ncha kalafong e tsoelang pele ea renal replacement therapy (CRRT), dialysis e tsoelang pele e sa sebetseng hantle (letsatsi le letsatsi) (CLED) le phapanyetsano ea plasma ea kalafo (TPE) e nang le citrate anticoagulation. Sehlahisoa sena se loketse batho ba baholo le bana" 'me sa bolela mabaka a ho se kenyelletsoe litekong tsa bongaka tsa mohato oa III le oa IV.
Komiti e hlokometse hore sehlahisoa sena se amohetsoe linaheng tsa Europe tse kang Portugal, United Kingdom, Brazil, Switzerland, Fora le Denmark.
Motsoako oa calcium chloride dihydrate ke CaCl2 2H2O, e leng calcium chloride e nang le limolek'hule tse peli tsa metsi ka yuniti ea calcium chloride. Ke ntho e tšoeu e kristale, e qhibilihang habonolo metsing 'me e le hygroscopic, ke hore, e khonang ho monya mongobo o tsoang moeeng.
Calcium chloride dihydrate ke motsoako o ka sebelisoang e le sistimi ea ho qhibilihisa chitin ha e qhibiliha ka har'a methanol. E bapala karolo ea bohlokoa ho robeng sebopeho sa kristale sa chitin 'me e na le mefuta e mengata ea ts'ebeliso lefapheng la k'hemistri.
Sebokeng sa SEC Nephrology se neng se tšoeroe ka la 20 Mots'eanong, 2025, phanele e ile ea hlahloba tlhahiso ea ho amohela tlhahiso le papatso ea tharollo ea calcium chloride dihydrate ea 100 mmol/L bakeng sa tšebeliso ho "phekolo ea calcium replacement therapy in continuous renal replacement therapy (CRRT), continuous low-efficiency (letsatsi le letsatsi) dialysis (SLEDD), le phetisetso ea plasma ea kalafo (TPE) ka citrate anticoagulation. Sehlahisoa sena se bontšoa ho batho ba baholo le bana" 'me se fane ka mabaka a ho se lokolloe litekong tsa kliniki tsa mohato oa III le oa IV.
Kamora puisano e qaqileng, komiti e khothalelitse hore motheo oa tumello, hammoho le lintlha tsa teko ea bongaka ea mohato oa III le lintlha tsa tlhokomelo ea kamora ho bapatsa tse tsoang linaheng tse amohetseng moriana, li romelloe komiting bakeng sa ho nahanoa ka ho eketsehileng.
Bala hape: Sehlopha sa CDSCO se Amohela ho Ngolwa ha Leiboleng ho Ntjhafaditsweng bakeng sa Myozyme ya Sanofi, se Kopela Tlhahlobo ya Taolo
Ngaka Divya Kolin ke moithuti ea fumaneng lengolo la PharmD ea nang le boiphihlelo bo bongata ba bongaka le sepetlele le tsebo e ntle ea ho hlahloba le ho phekola. O boetse a sebetsa e le rakhemisi oa kankere lefapheng la oncology ho Mysore Medical College and Research Institute. Hona joale o ntse a phehella mosebetsi oa hae oa lipatlisiso tsa bongaka le tsamaiso ea data ea bongaka. O 'nile a sebetsa le Medical Dialogue ho tloha ka Pherekhong 2022.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
Phuputso ea ABYSS e fumane hore ho emisa li-beta-blockers kamora ho tšoaroa ke pelo ho fella ka keketseho ea khatello ea mali, sekhahla sa pelo le liketsahalo tse mpe tsa pelo le methapo ea mali: …